Using Mirabegron to treat bedwetting in children
Is Mirabegron 25 mg Safe and Effective in Treatment of Primary Nocturnal Enuresis as Regard Oral Desmopressin 120 mcg?
This study is testing if a new medication called Mirabegron can help children who wet the bed at night feel better compared to the usual treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 5 Years to 15 Years |
| Sex | All |
| Sponsor | Benha University Academic / other |
| Locations | 1 site (Banhā, Qaliopia) |
| Trial ID | NCT05617664 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness and safety of Mirabegron 25 mg in treating primary nocturnal enuresis in children, comparing it to the standard treatment of oral Desmopressin 120 mcg and behavioral therapy. Nocturnal enuresis, a common condition affecting children, involves involuntary urination during sleep and can significantly impact quality of life. The study aims to determine if Mirabegron can provide a better therapeutic option for children who experience this condition. Participants will be monitored for their response to the medication and any side effects that may arise.
Who should consider this trial
Good fit: Ideal candidates are children diagnosed with primary nocturnal enuresis who experience wetting at least four times over four weeks and have no underlying neurological or urological issues.
Not a fit: Patients with secondary enuresis, neurological disorders, or those who have previously used anti-enuresis medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a more effective and safer option for managing bedwetting in children.
How similar studies have performed: While Desmopressin is a common treatment, the use of Mirabegron for this condition is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * primary nocturnal enuresis, * negligible daytime wetting, * wet at least 4 times over 4 weeks * normal clinical examination with no neurological or urological cause for the enuresis Exclusion Criteria: * secondary enuresis, polysymptomatic * neurologic bladder, neurological disorders, * urinary incontinence disorders * previous anti NE drugs.
Where this trial is running
Banhā, Qaliopia
- Benha University Hospitals — Banhā, Qaliopia, Egypt (Recruiting)
Study contacts
- Study coordinator: hosam abu el-nasr, MD
- Email: hosamabuelnasr@gmail.com
- Phone: 01286296939
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.